STENTYS is strengthening its Board by co-opting two new independent members

- Prof. Christian Spaulding, Head of the Interventional Cardiology department at the Georges-Pompidou European Hospital in Paris
- Sophie Baratte, CEO of medical technology company Cellnovo

PARIS - April 3, 2017 – 6 pm CET - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the XPOSITION S self-apposing coronary stent, today announces that the STENTYS Board of Directors has decided to co-opt Professor Christian Spaulding and Mrs. Sophie Baratte as independent Board members.

Professor Christian Spaulding is Professor of Cardiology at Paris Descartes University and Head of the Interventional Cardiology department at the Georges-Pompidou European Hospital, Paris. A member of the Cardiac Arrest Research Center at the PARCC Institute (Paris Cardiovascular Research Center), he has published more than 240 research articles in world-renown peer-reviewed scientific journals, notably on the issue of coronary stents and percutaneous coronary intervention techniques.

Mrs. Sophie Baratte is Chief Executive Officer of medical technology company Cellnovo. She has spent the majority of her career in senior positions at major healthcare companies such as Johnson & Johnson, Sorin Group, CIT and Lifecell. She thus has extensive experience in sales and marketing, notably in bringing innovative technologies to market.

Subject to these appointments being approved by the Annual General Meeting of May 11, 2017, Stentys’ 5-member Board of Directors will thus have 4 independent directors.

Michel DARNAUD, Chairman of the Board, comments: “I am delighted to welcome to our Board of Directors two experts who will be able to support us in the implementation of our growth strategy: Professor Christian Spaulding, interventional cardiologist, international expert, who heads the Interventional Cardiology department at the Georges-Pompidou European Hospital, and Sophie Baratte, who has substantial experience in the sales and marketing of innovative medical devices. Thanks to their respective know-how, we have solid assets to enable us to continue taking STENTYS forward and upward to become a benchmark player in its field”.

Upcoming financial publication:

STENTYS expects to publish its revenues for the 1st quarter of 2017 on Monday April 24, 2017

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America. More information is available at www.stentys.com
STENTYS
Christophe Lottin
CEO
Tel.: +33 (0)1 44 53 99 42
investor@stentys.com

NewCap
Investor Relations / Strategic Communications
Dusan Oresansky
Tel.: +33 (0)1 44 71 94 92
stentys@newcap.eu

STENTYS is listed on Compartment C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT

Safe Harbor Statements
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2015 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on August 30, 2016 under number D.16-804.